JP5525812B2 - Ｍｅｋインヒビターとしての新規ヘテロアリール置換アリールアミノピリジン誘導体 - Google Patents
Ｍｅｋインヒビターとしての新規ヘテロアリール置換アリールアミノピリジン誘導体 Download PDFInfo
- Publication number
- JP5525812B2 JP5525812B2 JP2009506558A JP2009506558A JP5525812B2 JP 5525812 B2 JP5525812 B2 JP 5525812B2 JP 2009506558 A JP2009506558 A JP 2009506558A JP 2009506558 A JP2009506558 A JP 2009506558A JP 5525812 B2 JP5525812 B2 JP 5525812B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- atoms
- unsubstituted
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC**CC*=CC1C(C)C*CC1 Chemical compound CC**CC*=CC1C(C)C*CC1 0.000 description 8
- RLJUIRVRCMKPBK-UHFFFAOYSA-O CC(C)(C)[SH+]c1c(-c2ccncc2NC(CCC(I)=C2)C2F)nn[nH]1 Chemical compound CC(C)(C)[SH+]c1c(-c2ccncc2NC(CCC(I)=C2)C2F)nn[nH]1 RLJUIRVRCMKPBK-UHFFFAOYSA-O 0.000 description 1
- LRTJIECEYWHWAM-UHFFFAOYSA-N CC(C)=NNC(O)=O Chemical compound CC(C)=NNC(O)=O LRTJIECEYWHWAM-UHFFFAOYSA-N 0.000 description 1
- ZVGKPQCCKGLQPB-UHFFFAOYSA-N CC(O1)=NNC1=S Chemical compound CC(O1)=NNC1=S ZVGKPQCCKGLQPB-UHFFFAOYSA-N 0.000 description 1
- LHNGDIIIISTEMW-UHFFFAOYSA-N COC(c(c(-c(cccc1)c1Cl)cnc1)c1Nc(c(F)c1)ccc1I)=O Chemical compound COC(c(c(-c(cccc1)c1Cl)cnc1)c1Nc(c(F)c1)ccc1I)=O LHNGDIIIISTEMW-UHFFFAOYSA-N 0.000 description 1
- XXIYUKKDKFWXMD-UHFFFAOYSA-N Fc(cc(cc1)I)c1Nc(cncc1)c1-c1c[nH]cn1 Chemical compound Fc(cc(cc1)I)c1Nc(cncc1)c1-c1c[nH]cn1 XXIYUKKDKFWXMD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79307306P | 2006-04-19 | 2006-04-19 | |
| US60/793,073 | 2006-04-19 | ||
| PCT/US2007/009456 WO2007123936A1 (en) | 2006-04-19 | 2007-04-18 | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009534386A JP2009534386A (ja) | 2009-09-24 |
| JP2009534386A5 JP2009534386A5 (enExample) | 2013-09-12 |
| JP5525812B2 true JP5525812B2 (ja) | 2014-06-18 |
Family
ID=38357968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506558A Expired - Fee Related JP5525812B2 (ja) | 2006-04-19 | 2007-04-18 | Ｍｅｋインヒビターとしての新規ヘテロアリール置換アリールアミノピリジン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8076486B2 (enExample) |
| EP (1) | EP2013180A1 (enExample) |
| JP (1) | JP5525812B2 (enExample) |
| KR (1) | KR20090005195A (enExample) |
| CN (2) | CN103121996B (enExample) |
| AR (1) | AR060807A1 (enExample) |
| AU (1) | AU2007240860A1 (enExample) |
| BR (1) | BRPI0711625A2 (enExample) |
| CA (1) | CA2644425A1 (enExample) |
| EA (1) | EA200802050A1 (enExample) |
| IL (1) | IL194546A0 (enExample) |
| MX (1) | MX2008013308A (enExample) |
| WO (1) | WO2007123936A1 (enExample) |
| ZA (1) | ZA200807263B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007123939A2 (en) * | 2006-04-19 | 2007-11-01 | Laboratoires Serono S.A. | Novel arylamino n-heteraryls as mek inhibitors |
| EP2231636B1 (en) * | 2007-12-07 | 2011-09-14 | Novartis AG | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| EP2370568B1 (en) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| CA2789696C (en) | 2010-02-25 | 2017-11-07 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| EP2545187B1 (en) | 2010-03-09 | 2018-09-05 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| US9630976B2 (en) | 2012-07-03 | 2017-04-25 | Ono Pharmaceutical Co., Ltd. | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
| WO2016142894A1 (en) * | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators |
| MA42145B1 (fr) | 2015-05-20 | 2020-05-29 | Amgen Inc | Triazoles agonistes du récepteur apj |
| US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| EP3541802B1 (en) | 2016-11-16 | 2025-01-01 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| US11186554B2 (en) | 2017-05-03 | 2021-11-30 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| WO2019040380A1 (en) | 2017-08-21 | 2019-02-28 | Vivace Therapeutics, Inc. | BENZOSULFONYL COMPOUNDS |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| WO2019113236A1 (en) | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
| EP3720438B1 (en) * | 2017-12-07 | 2023-08-30 | Amplyx Pharmaceuticals, Inc. | Heterocycle substituted pyridine derivative antifungal agents |
| CN110317190A (zh) * | 2018-03-28 | 2019-10-11 | 首都医科大学 | 一种三唑-羧酸酯类衍生物在医药领域的应用 |
| EP3788037A1 (en) | 2018-05-01 | 2021-03-10 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| CA3100503A1 (en) | 2018-05-16 | 2019-11-21 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| CN115279368B (zh) * | 2019-11-20 | 2024-05-24 | 维瓦斯治疗公司 | 杂芳基化合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| JP2024521788A (ja) | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス， インコーポレイテッド | 併用療法 |
| CN118973580A (zh) | 2022-04-08 | 2024-11-15 | 米拉蒂治疗股份有限公司 | 包含sos1抑制剂和mek抑制剂的组合疗法 |
| WO2025054260A1 (en) * | 2023-09-07 | 2025-03-13 | Kinnate Biopharma Inc. | Inhibitors of mek kinase |
| EP4788839A1 (en) | 2023-10-03 | 2026-08-12 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002534515A (ja) * | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | １−複素環置換されたジアリールアミン |
| GB2373245A (en) * | 2001-03-12 | 2002-09-18 | Bayer Ag | Pyridinyl pyrazoles and their use for the treatment of COPD |
| BR0314195A (pt) * | 2002-09-10 | 2005-07-26 | Pharmacia Italia Spa | Derivados de piridina substituìda como agentes antitumorais |
| AU2003293376A1 (en) * | 2002-12-10 | 2004-06-30 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
| US20050004186A1 (en) * | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| AU2004229392A1 (en) * | 2003-04-09 | 2004-10-28 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US20090048301A1 (en) | 2003-07-09 | 2009-02-19 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| KR101190912B1 (ko) | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법 |
| ES2444866T3 (es) * | 2004-10-20 | 2014-02-27 | Merck Serono Sa | Derivados de 3-arilamino piridina |
-
2007
- 2007-04-18 EA EA200802050A patent/EA200802050A1/ru unknown
- 2007-04-18 CN CN201210488042.5A patent/CN103121996B/zh not_active Expired - Fee Related
- 2007-04-18 KR KR1020087028187A patent/KR20090005195A/ko not_active Withdrawn
- 2007-04-18 AU AU2007240860A patent/AU2007240860A1/en not_active Abandoned
- 2007-04-18 WO PCT/US2007/009456 patent/WO2007123936A1/en not_active Ceased
- 2007-04-18 US US11/788,032 patent/US8076486B2/en not_active Expired - Fee Related
- 2007-04-18 BR BRPI0711625-0A patent/BRPI0711625A2/pt not_active IP Right Cessation
- 2007-04-18 MX MX2008013308A patent/MX2008013308A/es not_active Application Discontinuation
- 2007-04-18 JP JP2009506558A patent/JP5525812B2/ja not_active Expired - Fee Related
- 2007-04-18 CA CA002644425A patent/CA2644425A1/en not_active Abandoned
- 2007-04-18 CN CN200780014073.4A patent/CN101426766B/zh not_active Expired - Fee Related
- 2007-04-18 EP EP07755648A patent/EP2013180A1/en not_active Withdrawn
- 2007-04-18 ZA ZA200807263A patent/ZA200807263B/xx unknown
- 2007-04-19 AR ARP070101677A patent/AR060807A1/es unknown
-
2008
- 2008-10-06 IL IL194546A patent/IL194546A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008013308A (es) | 2008-10-27 |
| CN101426766B (zh) | 2014-03-26 |
| EA200802050A1 (ru) | 2009-04-28 |
| CN103121996B (zh) | 2015-10-21 |
| US8076486B2 (en) | 2011-12-13 |
| AR060807A1 (es) | 2008-07-16 |
| ZA200807263B (en) | 2009-11-25 |
| CN103121996A (zh) | 2013-05-29 |
| EP2013180A1 (en) | 2009-01-14 |
| AU2007240860A1 (en) | 2007-11-01 |
| US20070287737A1 (en) | 2007-12-13 |
| CN101426766A (zh) | 2009-05-06 |
| KR20090005195A (ko) | 2009-01-12 |
| WO2007123936A1 (en) | 2007-11-01 |
| BRPI0711625A2 (pt) | 2011-12-06 |
| HK1127354A1 (en) | 2009-09-25 |
| CA2644425A1 (en) | 2007-11-01 |
| IL194546A0 (en) | 2009-08-03 |
| JP2009534386A (ja) | 2009-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009534386A (ja) | Ｍｅｋインヒビターとしての新規ヘテロアリール置換アリールアミノピリジン誘導体 | |
| ES2605388T3 (es) | Compuesto inhibidor de Trk | |
| ES2791315T3 (es) | Agonistas triazoles del receptor APJ | |
| JP5331681B2 (ja) | ｃ−ｆｍｓキナーゼの阻害剤 | |
| US9914736B2 (en) | TrKA kinase inhibitors, compositions and methods thereof | |
| CN106061974B (zh) | 作为wnt途径的调节剂的顺丁烯二酰亚胺衍生物 | |
| EP3206689B1 (en) | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof | |
| CN107207489A (zh) | 作为nadph氧化酶抑制剂的酰氨基噻二唑衍生物 | |
| KR20120088738A (ko) | 칼슘 방출-활성화 칼슘 통로의 조정제로서의 피라졸 유도체 | |
| KR20110031318A (ko) | Ｉａ 심부전 및 암 치료에 유용한 단백질 키나제 ｄ 억제제로서의 2,4'-비피리디닐 화합물 | |
| JP2007537163A (ja) | 化合物、組成物、および方法 | |
| JP2022532719A (ja) | Ａｃｓｓ２阻害剤およびその使用方法 | |
| CN101687852A (zh) | 可用作激酶抑制剂的噻唑类和吡唑类化合物 | |
| US20050234029A1 (en) | Compounds | |
| JP2024529487A (ja) | Ｒｏｃｋ２阻害剤およびその使用 | |
| KR20230043103A (ko) | 술폰아마이드 화합물 | |
| AU2005309760A1 (en) | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease | |
| CN116583501A (zh) | 用于治疗与lpa受体活性相关的病症的化合物和组合物 | |
| WO2021127301A1 (en) | 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorders | |
| WO2011093365A1 (ja) | 含窒素複素環化合物 | |
| TW201245187A (en) | Pyrazole derivatives | |
| US20060074244A1 (en) | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway | |
| HK1127354B (en) | Heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors | |
| HK40046551A (en) | Novel quinoline derivative inhibitor | |
| HK1138587A (en) | Thiazoles and pyrazoles useful as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100416 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121002 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121002 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130129 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130426 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130508 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20130729 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130820 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140220 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140318 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140414 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5525812 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |